Ionis Pharmaceuticals

Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects
Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects
Xconomy
Ionis Pharmaceuticals
Huntington's disease
clinical trials
tominersen
Flag link:
Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment
Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment
Motley Fool
Akcea Therapeutics
Ionis Pharmaceuticals
hypertriglyceridemia
AKCEA-ANGPTL3-Lrx
clinical trials
Flag link:
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
EP Vantage
Karyopharm
Xpovio
Multiple Myeloma
Pfizer
Akcea
Ionis Pharmaceuticals
AKCEA-ANGPTL3-Lrx
Flag link:
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
BioSpace
Biogen
Alzheimer's disease
IONIS-MAPTRx
Ionis Pharmaceuticals
Flag link:
These Biotechs Were Focused on One Line on Pfizer’s Earnings Report
These Biotechs Were Focused on One Line on Pfizer’s Earnings Report
Motley Fool
Pfizer
Vyndaqel
Alnylam
Akcea Therapeutics
Ionis Pharmaceuticals
Eidos Therapeutics
Flag link:
Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development
Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development
Endpoints
Bayer
Ionis Pharmaceuticals
Factor XI
anti-thrombotics
clinical trials
IONIS-FXI-LR
Flag link:
Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M
Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M
Xconomy
Pfizer
Akcea
Ionis Pharmaceuticals
heart disease
AKCEA-ANGPTL3-Lrx
Flag link:
A Biotech Set to Dominate the Next 20 Years
A Biotech Set to Dominate the Next 20 Years
Motley Fool
Ionis Pharmaceuticals
Flag link:
GSK licenses Ionis' midphase hepatitis B program for $25M
GSK licenses Ionis' midphase hepatitis B program for $25M
Fierce Biotech
GSK
Ionis Pharmaceuticals
antisense
hepatitis B
Flag link:
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Motley Fool
Ionis Pharmaceuticals
Flag link:
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
BioSpace
Biogen
tofersen
antisense
Ionis Pharmaceuticals
ALS
Flag link:
'Pathbreaking' Ionis trial offers way forward in Huntington's disease
'Pathbreaking' Ionis trial offers way forward in Huntington's disease
Biopharma Dive
Ionis Pharmaceuticals
Roche
Huntington's disease6
RG6042
Flag link:
Ionis slides after AveXis reports SMA data for Zolgensma
Ionis slides after AveXis reports SMA data for Zolgensma
BioCentury
Ionis Pharmaceuticals
AveXis
Zolgensma
lcinical trials
spinal muscular atrophy
Flag link:
1 Biotech That Biogen Should Buy ... but Probably Won't
1 Biotech That Biogen Should Buy ... but Probably Won't
Motley Fool
Biogen
Ionis Pharmaceuticals
M&A
Flag link:
Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs
Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs
Motley Fool
Ionis Pharmaceuticals
earnings
Flag link:
Novartis aims to pump up cardio business with Ionis deal
Novartis aims to pump up cardio business with Ionis deal
Yahoo/Reuters
Novartis
Ionis Pharmaceuticals
TQJ230
Flag link:
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Biopharma Dive
R&D
Moderna Therapeutics
Sarepta Therapeutics
Ionis Pharmaceuticals
Flag link:
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
BioCentury
BIIB067
Biogen
Ionis Pharmaceuticals
ALS
Flag link:
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Biopharma Dive
Akcea Therapeutics
Ionis Pharmaceuticals
clinical trials
Novartis
AKCEA-APO(a)-Lrx
Flag link:
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
type 2 diabetes
antisense
Flag link:

Pages